Skip to main content
227 results:
51. New data on innovative biomarkers used to guide the clinical management of septic patients  
Uniklinik RWTH Aachen and SphingoTec GmbH announce today that novel data on the acute care biomarkers bio-ADM and penKid will be presented at the 40th ISICEM.  
52. SphingoTec Appoints Dr. Gerald Möller as Chairman of the Advisory Board  
Diagnostics company SphingoTec GmbH announces that Dr. Gerald Möller has joined the company’s advisory board as chairman of the board.  
53. SphingoTec Expands Management Team and Appoints new CFO  
Diagnostics company SphingoTec GmbH (“SphingoTec”) announces the appointment of Dr. Angelo Moesslang as new chief financial officer (CFO) and managing director.  
54. SphingoTec Accelerates Growth with Direct Sales  
Diagnostics company SphingoTec GmbH (“SphingoTec”) announces an expansion of its go-to-market strategy to scale its sales in Germany by creating a direct sales force for its integrated diagnostic…  
55. Endothelial Function Biomarker bio-ADM to Support Risk Stratification and Clinical Management of COVID-19 Patients  
German University Hospital Uniklinik RWTH Aachen and diagnostics company SphingoTec GmbH today announced that the endothelial function biomarker bio-ADM aids in the early risk stratification and…  
56. New diagnostic tool for the management of patients with sepsis: Dipeptidyl Peptidase 3 (DPP3)  
Diagnostics company SphingoTec GmbH (“SphingoTec”) announced today the first published data (1) on the biomarker DPP3 that can predict the evolution of organ function and survival in septic patients.…  
Search results 51 until 60 of 227